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 PTo validate thepotential anti-inﬂammatory and analgesic role of sita- and vildagliptin,ﬁve different experimentalmodels were used inmice: i)mustard oil-induced ear edema, ii) neutrophil accumulation, iii)mechanical and iv)thermal touch sensitivity in complete Freund's adjuvant-induced arthritis and v) capsaicin-induced plasma
extravasation in the urinary bladder. For the complete examination period in i) the dose of 10 mg sitagliptin as
well as 1–10 mg vildagliptin was found to signiﬁcantly decrease ear edema as compared to positive control
(p b 0.05, n = 8/group). All doses of sitagliptin provided an anti-inﬂammatory effect p b 0.005 (n = 10/
group) in test ii) and an analgesic effect in iii) except 3 mg. Vildagliptin was similarly effective in test ii)
(p b 0.005, n = 10/group) as sitagliptin, but it failed to affect mechanical touch sensitivity. Unlike mechanical
touch sensitivity, both gliptins could beneﬁcially act on the thermal threshold (p b 0.05, n = 10/group). And
only in tests v) could both gliptins reverse inﬂammation. Further studies are needed to support the suggestion
that the utilization of these beneﬁcial effects of gliptins may be considered in the treatment of Type 2 diabetic
patients.
























Chronic inﬂammation and pain can be highly debilitating. To reduce
the inﬂammation itself or to relieve the related pain is a justiﬁable
expectation of the patients. Anti-inﬂammatory and analgesic drugs are
commonly prescribed for the symptomatic treatment of different
diseases and the range of chemical classes of available drugs is quite
broad. The most frequently used drugs are the non-steroidal anti-
inﬂammatory drugs, although the application of steroid compounds in
serious cases is also widely accepted. The conditions when these drugs
are applied are mostly immune-driven diseases like multiple sclerosis,
inﬂammatory bowel disease, or rheumatoid arthritis. Moreover, diabe-
tes related pain such as diabetic neuropathy or painful diabetic neuritis
afﬂicts a majority of diabetic patients especially, if the diabetes is not
treated adequately.
Since diabetes (especially type-2 diabetes) has a growing prevalence
worldwide, novel treatments of the disease are in the focus of scientiﬁc
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06drug categories are the degradation-resistant glucagon-like peptide-1
(GLP-1) receptor agonists (incretin mimetics) and the inhibitors of
dipeptidyl peptidase-4 (DPP-4) activity (incretin enhancers) [1]. The
pharmacological actions of GLP-1 analogues and DPP-4 inhibitors have
been reviewed recently [2].
There are intestinal hormones released after the oral administration
of glucose. These hormones are released in a glucose-dependent man-
ner and are responsible for augmenting insulin secretion, promoting ß
cell proliferation and reducing apoptosis. This is deﬁned as the incretin
effect. The two most important hormones involved in the incretin
mechanism are the glucose-dependent insulinotropic polypeptide
(GIP) and GLP-1 [1,3]. Both GIP and GLP-1 are rapidly inactivated after
their release; the half-life of active GLP-1 being less than 2 minutes.
The inactivation is caused by a truncation of the peptides by the removal
of the N-terminal peptide end. This process is executed by the enzyme
dipeptidyl peptidase-4 (DPP-4) [4]. DPP-4 is a 110-kDa type-II integral
membrane glycoproteinwith ubiquitous expression andwhose enzyme
activity has been recorded in rats, mice and humans. It is present in the
epithelial cells of the intestine, kidney, liver, lung, thymus, lymph node,
spleen, prostate and in adipocytes, as well as on activated lymphocytes
and monocytes [5]. Besides the incretin hormones, a number of
bioactive peptides are potential substrates for DPP-4. These include




































































































































adenylate-cyclase-activating polypeptide, insulin-like growth factor-1,
substance P and various chemokines [6]. DPP-4 is also known as the
cell surface antigen CD26 and it can associate with the lymphocyte
cell-surface molecules CD45 and adenosine deaminase (ADA) to have
a co-stimulatory function in the immune response [5]. An interesting
observation is the increase in the plasma concentration of DPP-4 as a
soluble protein during continuous treatment of humans by sitagliptin
(100 mg/day). This might originate from shedding of CD26 proteins
from mononuclear cells evoked by sitagliptin [8].
Dipeptidyl peptidase-4 inhibitors, like sitagliptin and vildagliptin,
have been already introduced to the market since 2006 and are used
for the treatment of type-2 diabetes. Gliptins are found to improve the
vascular endothelial function, thus performing pleiotropic cardiovascu-
lar actions [7]. The safety of the gliptin family was questioned recently,
but in two long-term cardiovascular outcome trials, Saxagliptin Assess-
ment of Vascular Outcomes Recorded in Patients with Diabetes
Mellitus-THrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53),
it has been proven that saxagliptin is safe from the cardiovascular
point of view. It was shown that the primary endpoints of the study (a
composite of cardiovascular death, non-fatal myocardial infarction or
non-fatal ischemic stroke) occurred in 7.3% of the saxagliptin group
compared with 7.2% of the placebo group (ClinicalTrials.gov Identiﬁer:
NCT01107886). The conclusion of Cardiovascular Outcomes Study of
Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syn-
drome (EXAMINE) study (ClinicalTrials.gov Identiﬁer: NCT00968708)
was that in type-2 diabetic patients with recent acute coronary
syndrome, major cardiovascular event rates for alogliptin were not
increased compared to placebo. In this trial acute pancreatitis develop-
ment as a serious adverse event was only 0.07% compared to placebo
(0.15 %), thus it is valid to state that alogliptin is free from this side effect.
Both incretins, GIP andGLP-1 stimulate insulin secretion in a glucose
dependent manner and consequently, DPP-4 inhibitor treatment does
not increase the risk of hypoglycaemia. Not only was the occurrence of
hypoglycaemic events incidentally similar or lower when comparing
groups treated with DPP-4 inhibitor (either monotherapy or in combi-
nation)with placebo treated groups in different studies, but the number
of reported adverse events did not differ from the actively treated
groups. [4]. It has been demonstrated in animal studies that toxicity
may be caused by the inhibition of other enzymes in this family, like
DPP-8 and DPP-9 [9], so the selectivity of inhibitors to DPP-4 is crucially
important to ensure an optimal safety proﬁle. Since both sitagliptin and
vildagliptin show a higher relative selectivity for DPP-4, the risk of
development of adverse effects due to inhibition of other enzymes is
minimized [4,10]. However, it did turn out that during the postmarket-
ing period of gliptins these DPP-4 inhibitors increased the rate of infec-
tions such as nasopharyngitis and urinary tract infections [11]. In
addition, pancreatitis was reported mainly associated with the use of
sitagliptin and linagliptin [12], although a recent meta-analysis could
not ﬁnd differences between DPP-4 inhibitors [13]. In spite of the in-
creased risk of infections, sitagliptin and vildagliptin are well tolerated
in general. Besides the primary targeted therapeutic area, in vitro and
in vivo studies showed anti-inﬂammatory properties of DPP-4 inhibitors
that could lead to a novel drug class for anti-inﬂammatory disorders
[14]. Altered circulating peptidase activity and membrane DPP-4
expression have been demonstrated in a number of human inﬂammato-
ry diseases [15]. DPP-4 is responsible for themodiﬁcation of a number of
regulatory factors, such as peptides or chemokines and affects the
signaling functions. This suggests that DPP-4 is involved in determining
immune response and procession of inﬂammatory disorders as well. As
mentioned previously, DPP-4 is also known as the cell surface antigen
CD26, which signals T-cells to proliferate. However, this mechanism
cannot be attributed to the DPP-4 inhibition [16] because the T-cell
activation seems to be independent of the DPP-4 enzyme activity and
the ADA-binding capability [16,17]. Moreover, reversible DPP-4 inhibi-
tor Lys[Z(NO2)]-pyrrolidide was shown to suppress autoimmune








The possible anti-inﬂammatory property of the gliptin group can
be considered as an additional value of these drugs in diabetic
patients with neuritis or diabetic neuropathy, or patients with
atherosclerosis considering that these diseases are driven by inﬂam-
matory processes [19]. Moreover, the reduction in plasma C-reactive
protein concentration and systolic blood pressure have been
described for exenatide [20]. The anti-inﬂammatory action of
sitagliptin [8] and exenatide [19] are proven biochemically in
humans, thus in the present series of experiments we aimed to
examine the possible anti-inﬂammatory effect of two potent DPP-4
inhibitors, sitagliptin and vildagliptin. They were applied in in vivo
inﬂammation and analgesic models in mice.
2. Materials and methods
2.1. Animals and ethics
Experiments were performed on 25–35 g CD1 male mice (Charles
River, Gödöllő, Hungary), kept under standard pathogen-free conditions
at 24–25 °C and provided with standard rodent chow and water
ad libitum. The light/dark cycle was 12 h/12 h. Animal procedures
were approved by the local animal ethics committee and National
Food Chain Safety Ofﬁce Animal Health and AnimalWelfare Directorate
under the number 26/2007/DE MÁB in accordance with the European
Communities Council Directives (86/609/ECC) and the Hungarian Act
for the Protection of Animals in Research (XXVIII tv. 32§) and complied
with the recommendations of the International Association for the
Study of Pain [21] and the Helsinki Declaration. The design of the
study was carried out in a manner in which to minimize the number
of animals used and their suffering.
2.2. Substances and their application
Mice were dosed with 1, 3 or 10 mg/kg sitagliptin or vildagliptin
(Nanjing Ange Pharmaceuticals, Nanjing, Jiangsu, China) dissolved in
saline by oral gavage (1 ml/100 g). Control groups were given the
vehicle in the same amount and way. A single application was used in
the case of one-day experiments, while daily application was used in
the 21 day long experiments, as suggested by Thomas et al. [22].
Treatments and measurements were implemented 30 min after the
oral gavage in every case.
2.3. Allyl-isothiocyanate (AITC)-induced inﬂammation model
Anesthesia was induced by thiopental (Trapanal, Sandoz, Basle,
Switzerland) in an amount of 50 mg/kg intraperitoneally (i.p.), repeat-
ed as required. The inner and outer surface of the right ear was then
smeared with 1% allyl-isothiocyanate (AITC) (Sigma-Aldrich, Budapest,
Hungary) dissolved in parafﬁn oil, using a cotton-wool stick. This treat-
ment was applied 30min after the oral gavage (substances dissolved in
saline or vehicle in the control group) and the procedure was repeated
45min after the ﬁrst application following the instructions of Bánvölgyi
[23] and Inoue et al. [24]. Thus the oral administration of gliptins was
performed ﬁrstly and the induction of inﬂammation was carried out
secondly.
At the end of the experiment the animals were sacriﬁced by cervical
dislocation and ears were stored on -20 °C for the neutrophil accumula-
tion assay.
2.4. Measurement of ear edema
Ear thickness was measured by a micrometer caliper (Oxford Preci-
sion, Leicester, England) with 0.1 mm accuracy before the AITC treat-
ment, 15 min after the ﬁrst AITC application, then by each hour during
a 6 hour period after each AITC treatment according to Inoue et al. [24]

















































































before the commencement of ear edema induction. Datawere expressed
in micrometers.
2.5. Measurement of neutrophil accumulation
Frozen ear sampleswere thawed at room temperature, chopped into
small pieces, and homogenized in 0.05 M potassium phosphate buffer
containing 0.5% HTAB (hexadecyltrimethylammonium bromide,
Sigma-Aldrich, Budapest, Hungary), 1 ml buffer/ear. The homogenate
was centrifuged at 11000 g at 4 °C for 10min and 200 μl of the superna-
tant was placed into Eppendorf tubes.
Myeloperoxidase activity was assayed by measuring the H2O2-
dependent oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma-
Aldrich, Budapest, Hungary) as suggested by Suzuki et al. [25]. In its
oxidized form, TMB has a blue color, which was measured spectropho-
tometrically at 620 nm. The reaction was performed in 96-well microti-
ter plates at room temperature. The reaction mixture consisted of 25 μl
of the tissue sample, 25 μl of TMB (ﬁnal concentration 0.16 mM)
dissolved in dimethylsulfoxide (DMSO) and 200 μl H2O2 (ﬁnal concen-
tration 0.24 mM, Sigma-Aldrich, Budapest, Hungary) diluted in 0.08 M
phosphate buffer pH 5.4 after Schierwagen et al. [26]. The optical densi-
ty (OD) was measured at 5 min intervals for 30 min using a microplate
reader (FLUOstar OPTIMA, BMG Labtech, Ortenberg, Germany). Data
was expressed in arbitrary units of absorbance.
2.6. Induction of arthritis
Chronic arthritis of the right tibiotarsal joint of mice was induced by
the subcutaneous injection of 0.1 ml of Freund's complete adjuvant
(CFA, killed Mycobacteria suspended in parafﬁn oil, 1 mg/ml as provid-
ed by Sigma-Aldrich, Budapest, Hungary) into the plantar surface of the
right hind paw and root of the tail. To enhance systemic effects, an addi-
tional injection into the tail was given the following day as described by
Helyes et al. [27]. In order to minimize the suffering of mice, short-term
general anesthesia was induced by 1% isoﬂurane (Abbott Laboratories,
Budapest, Hungary) delivered in 1:2 oxygen/nitrous oxide mixture.
2.7. Measurement of plasmaextravasation in the urinary bladder of mice
Mice were anaesthetized by i.p. administration of thiopental
(50 mg/kg). A lateral tail vein was cannulated for intravenous adminis-
tration. 1 or 3 mg of vildagliptin or sitagliptin was administered by oral
gavage 30 minutes before the commencement of the capsaicin chal-




Fig. 1. Time evolution of baseline corrected ear thickness (μm) in allyl-isothiocyanate (AIT
B) vildagliptin administered by oral gavage. Error bars denote standard error of the mean. L
# (p b 0.005), and $ (p b 0.001) showed signiﬁcant differences to positive control, 1 mg, and 3
respectively as assessed by Games-Howell post hoc test.








was injected through the venous cannula. Each animal was sacriﬁced
by transcardiac perfusion with 50ml of 0.9%w/v saline into the left car-
diac ventricle 10 min after intravenous injection of Evans blue at 37 °C.
The urinary bladder was then removed and weighed. Excised tissues
were incubated in 1 ml of formamide for 48 h and Evans blue content
was measured spectrophotometrically at 620 nm and expressed as
μg/g wet mass of the tissue.
2.8. Measurement of mechano-nociceptive threshold
Touch sensitivity on the plantar surfacewasmeasuredwith von Frey
ﬁlaments (Bioseb, Chaville, France) before the experiment, 3, 7, 10, 14,
17, and 21 days following the ﬁrst CFA administration. The set of 20
monoﬁlaments provided an approximate logarithmic scale of actual
force and a linear scale of perceived intensity. Mice were placed into a
Plexiglas cage with a pitted ﬂoor. Following animal acclimatization the
operator placed the monoﬁlament under the animal's paw and pressed
against the surface till the animal indicated the pressure sensation by
pulling back or shaking its paw, or the monoﬁlament curved without
any kind of reaction starting with 0.008 g and ranging up to 300 g.
2.9. Increasing-temperature hot plate test
The plate (Supertech, Pécs, Hungary) in contact with the paws has
been slowly warmed up from room temperature and the threshold
temperature producing the ﬁrst nocifensive behavior (e.g., paw licking)
was recorded. Since the temperature was increased gradually into the
noxious range, stress associated with the testing procedure was mini-
mized. The heated surface dimensions were 110 × 80 mm surrounded
by 350mmhigh transparent Plexiglas walls. The commanding comput-
er program was set to produce a 3 °C/min temperature increase of the
plate as proposed by László et al. [28]. When the hind paw licking or
ﬂinching was observed the threshold temperature was recorded. The
measurement was terminated at the threshold level or when the plate
temperature reached 50 °C to avoid tissue damage [29]. Data were
expressed in °C.
2.10. Statistics
Since baseline values of diverse groupswere signiﬁcantly different in
all measurements, a baseline correction was carried out on raw values.
Baseline corrected values were regarded as primary outcomemeasures.
Two-way ANOVAwith replication was used for multiple group analysis
with the time point of observation and the treatment option as factorsC)-induced ear edema model in mice as a function of the amount of A) sitagliptin and
ines between markers guide the eye only. For the complete time period × (p b 0.001),
mg sitagliptin, and × (p b 0.001), # (p b 0.01) to positive control and 1 mg vildagliptin,





































Fig. 2. Time evolution of the baseline corrected absorbance of myeloperoxidase in an allyl-isothiocyanate (AITC)-induced ear edema model in mice as a function of the amount of
A) sitagliptin or B) vildagliptin administered by oral gavage. Error bars denote standard error of the mean. Lines between markers guide the eye only. For the complete time period
* (p b 0.05) and × (p b 0.01) showed signiﬁcant differences to negative and positive control and * (p b 0.05), × (p b 0.005), # (p b 0.01), and $ (p b 0.005) to negative, positive control,
1 mg, and 3 mg vildagliptin, respectively as assessed by Games-Howell post hoc test.
4 J. Újhelyi et al. / Regulatory Peptides xxx (2014) xxx–xxxR
E
C
for the complete duration of the experiments. Games-Howell tests were
used as post hoc analysis for binary comparison of group averages.
Signiﬁcant differences at the 95% conﬁdence interval were recognized,
if p b 0.05. Below 0.001 no numeric values of p are provided in the text.
3. Results
3.1. AITC-induced ear edema
Both orally administered gliptins signiﬁcantly decreased ear thick-
ness in the complete time period compared to positive control (AITC
only) in a dose-dependent manner as seen in Fig. 1. The maximum
effect of AITC was measured at 2 hour post-challenge time in either
case. For the complete examination period 10 mg sitagliptin as well as
1–10 mg vildagliptin was found to signiﬁcantly decrease ear edema as
compared to positive control.
3.2. AITC-induced neutrophil accumulation
The evolved inﬂammation was shown by the high level of





Fig. 3. Time evolution of the mechano-nociceptive threshold in Freund's complete adjuvant
B) vildagliptin administered by oral gavage. Error bars denote standard error of the mean.
× (p b 0.01), and # (p b 0.05) showed signiﬁcant differences to negative, positive control
Games-Howell post hoc test.




RFig. 2. The model is suitable for measuring the extent of inﬂammation,since these data deﬁnitely diverge from the negative control group
results. Sitagliptin treatmentwas found signiﬁcantly effective in blocking
the evolution of inﬂammation; every examined dose could reverse in-
ﬂammation. (Blind sampleswere not included in the hypothesis testing.)
The effect of vildagliptin treatment was similar to that of sitagliptin,
although the dose of 3 mg/kg had only an insigniﬁcant impact.
3.3. Measurement of plasmaextravasation in the urinary bladder of mice
The capsaicin-induced plasma extravasation in urinary bladders of
mice was inhibited by sitagliptin (1 mg p= 0.025 and 3 mg p b 0.001)
and vildagliptin (both 1 mg and 3 mg p b 0.001) signiﬁcantly (Fig. 4).
Difference in action was seen between the higher doses (3 mg/kg) of
vilda- and sitagliptin. The lower dose of sitagliptin (1 mg/kg) produced
the least signiﬁcant inhibition compared to the control.
3.4. Touch sensitivity in CFA-induced arthritis
Results show that the mechano-nociceptive threshold of the un-
treated group was signiﬁcantly higher than in the CFA treated (positive(CFA)-induced arthritis model in mice as a function of the amount of A) sitagliptin or
Lines between markers guide the eye only. For the complete time period * (p b 0.001),
and 1 mg sitagliptin, and * (p b 0.001) to negative control, respectively as assessed by















































Fig. 4. Inhibition of capsaicin-induced plasmaextravasation in urinary bladders of mice by
Vildagliptin and Sitagliptin. Gliptins were administered by oral gavage in 1 or 3 mg/kg
dose 30 minutes before the capsaicin (1 mg/kg) intravenous challange. Evans blue dye
was administered in 30 mg/kg i.v. and the plasmaextravasation was determined spectro-
photometrically at 620 nm wave length. Error bars denote standard error of the mean.
* and × denote signiﬁcant differences to negative control and to vildagliptin 1 mg,
respectively as assessed by Games-Howell post hoc test.
5J. Újhelyi et al. / Regulatory Peptides xxx (2014) xxx–xxxcontrol) group during the whole 21 day experimental period (Fig. 3). In
the gliptin treated groups every threshold was signiﬁcantly lower
than in the negative control group; consequently neither sita-, nor
vildagliptin treatment was able to hinder the evolution of allodynia.
Sitagliptin was signiﬁcantly harmful in an amount of 3 and 10 mg/kg
doses as compared to the positive control, meanwhile vildagliptin












3.5. Increasing-temperature hot plate test in CFA-induced arthritis
Threshold temperature of the untreated group was signiﬁcantly
higher than in the CFA-treated group during the whole 21 day experi-
mental period, following the ﬁrst day as shown in Fig. 5. Every dose of
either sitagliptin or vildagliptin signiﬁcantly increased the threshold
temperature, compared to the positive control group. Neither sitagliptin
nor vildagliptin could inhibit inﬂammation; the threshold in all gliptin






Fig. 5. Time evolution of the thermo-nociceptive threshold in Freund's complete adjuvant
B) vildagliptin administered by oral gavage. Error bars denote standard error of the mean. L
× (p b 0.05), and # (p b 0.05) showed signiﬁcant differences to negative, positive control, and
positive control, 1 mg, and 3 mg vildagliptin, respectively as assessed by Games-Howell post h









According to our present data, we can conclude that the studied
gliptins had a dose-dependent anti-inﬂammatory effect in in vivo
mouse models. The applied methods were sensitive enough to detect
the action of gliptins. Dipeptidyl peptidase inhibitors were reviewed
as an emerging drug class for various inﬂammatory diseases [7]. The
anti-inﬂammatory action of these drugs were described in human stud-
ies [8] and for exenatide [19]. Sitagliptin signiﬁcantly improves endo-
thelial function and inﬂammatory state in patients with coronary
artery disease and uncontrolled diabetes mellitus [30], forming a mile-
stone in the way towards widening the spectrum of gliptins' indication.
Moreover, the GLP-1 receptor (GLP-1R) is expressed in lymphoid tissue
and the numbers of CD4+ and CD8+ T-cells in lymph nodes was
shown to increase after exenatide (a GLP-1R agonist) treatment. It
could also reduce the number of CD4+ CD25+ Foxp3 + regulatoryT-
cells in the thymus, but not in the spleen [31], thus playing a regulatory
role in the immune system and can inﬂuence inﬂammatory processes
[32]. However, Kim et al. [33] were unable to detect the effect of either
GIP or GLP-1 on splenic or thymic CD4+ T-cell migration in vitro [33].
Eosinophil cell recruitment (in allergic asthma or in atopic dermatitis)
is described to be mediated by CCL11(eosinophil chemotactic protein)
and the recruitment proved to be more effective after pharmacological
inhibition of DPP-4 enzyme or in DPP-4-deﬁcient F344 rats [34].The
activation of transient receptor potential ankyrin 1 (TRPA1) evokes
nociception through substance P release from the primary sensory neu-
rons; p38 mitogen-activated protein kinase (p38 MAPK) inhibitor
SB203580 signiﬁcantly attenuated AITC-evoked substance P release
[35]. Allyl-isothiocyanate is capable of inducing ear edema in the proper
dose as described earlier [23]; the maximum auricle swelling was
measured in the second hour. Both examined chemicals, sitagliptin
and vildagliptin were able to decrease the AITC-induced inﬂammation
in a dose-dependent manner however, sitagliptin had a higher impact.
This effect cannot be explained by the regulatory role of GLP-1 on p38
MAPK, as it was described as an inducer [36]; neither can it be attributed
to the effect of gliptins on substance P metabolism [37]. Moreover, the
physiological role of GLP-1 is so dominant that its inhibition can still
override the p38 MAPK-inducer property and the algogenic effect of
elevated substance P. Treatment by DPP4 inhibitor I40 signiﬁcantly
reduced the severity of experimental allergic encephalomyelitis (EAE),
in mice conceivably through up-regulating TGF-beta 1 [18]. Furthermore,
a dose-dependent inhibition of the secretion of the pro-inﬂammatory
cytokine TNF-alpha was measured in vitro [18]. The ability of gliptins to(CFA)-induced arthritis model in mice as a function of the amount of A) sitagliptin or
ines between markers guide the eye only. For the complete time period * (p b 0.001),
1 mg sitagliptin, and * (p b 0.001), × (p b 0.05), # (p b 0.05), and $ (p b 0.01) to negative,
oc test.




































































































































































regulate TNF-alpha, INF-gamma, and a variety of interleukins can be at-
tributed only to the DPP4 inhibitory activity, because the compounds
used in the present series of experiments have a high speciﬁcity to
DPP4 and probably do not have any inhibitory effect on DPP8 or 9 in
the applied doses [38]. However, vildagliptin ineffectiveness in two
models (myeloperoxidase measurement and touch sensitivity in CFA-
induced arthritis) at 3 mg/kg can be the result of DPP-9 activity attenua-
tion having 66 nM IC50 value in vitro compared to 130 nM IC50 for
sitagliptin [39]. Inhibition of DPP-8/9 can lead to the development of
adverse effects in rodents [9,40], but other studies state that the inhibition
of DPP-8/9 do not have any clinical consequence [41]. A reduced expres-
sion of nitrosative stress and inﬂammation hallmarks within the brain of
chronically administered sitagliptin was described earlier in a mouse
model of Alzheimer's disease [42]. An explanation could easily rise
considering the fact that GLP-1 can have growth-factor-like properties
similar to insulin and the anti-inﬂammatory activity is a secondary action
[43]. In our experiments, the anti-inﬂammatory action seems to be direct
as demonstrated by the accumulated number of neutrophil cells
(measured by myeloperoxidase enzyme activity) in the inﬂamed ear;
this accumulation could be inhibited by the gliptin pre-treatment.
Similarly to the above mentioned tests, sitagliptin treatment had a
higher impact in the compensation of the CFA-induced arthritis,
where vildagliptin showed no effectiveness. In case of measuring the
high temperature sensitivity, both substances showed equal effective-
ness. Our results lead to the conclusion that sitagliptin has a stronger
inﬂuence on the evolution of inﬂammation; however, vildagliptin
showed higher effectiveness in the inhibition of capsaicin-induced
plasma extravasation in the urinary bladder. Although the investigated
molecules have the same effectiveness in the treatment of type-2
diabetes, it seems that they do not act in the same way, in the immune
response. Both substances represent promising options for the therapy
of inﬂammatory disorders.
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